Israeli Pharma Giant Teva Buys Botox's Allergan
$40.5 billion purchase solidifies Teva as world leader in generic drugs, after $40.1 billion bid for rival Mylan meets resistance.
$40.5 billion purchase solidifies Teva as world leader in generic drugs, after $40.1 billion bid for rival Mylan meets resistance.
A team of researchers from Tel Aviv University and Harvard Medical School harnesses pulsed electric fields to stimulate new tissue.